New England Journal of Medicine , 375 (19), 18341844
For more information, visit BPC-157 Pure Synthetic peptide originally derived from a naturally occurring sequence found in human gastric proteins
There are now three GLP-1RA drugs approved in multiple countries [see Table 1] for chronic weight management, all of which are administered as injections: Wegovy (active substance semaglutide) and Saxenda (active substance liraglutide) from Novo Nordisk, and Mounjaro/Zepbound 1 (active substance tirzepatide) from Eli Lilly the latter being the first dual receptor agonist 2 drug approved
Studies have shown that Ozempic can lead to significant weight loss when used in individuals without diabetes
It helps regulate blood sugar, slows digestion, and reduces appetite, making it highly effective for managing type 2 diabetes and aiding weight loss
Clinical Evidence on Bone Density Studies evaluating the relationship between GLP1 therapy and bone outcomes have yielded mixed results